The ICD-10-CM code Z22.322 identifies individuals who are colonized with Methicillin-resistant Staphylococcus aureus (MRSA) but do not currently manifest an active clinical infection. Colonization occurs when the MRSA bacteria reside on the skin or within body sites, most commonly the anterior nares (nostrils), axilla, or groin, without causing host tissue damage or an inflammatory response. While carriers are asymptomatic, they serve as a reservoir for the pathogen, posing a significant risk for the transmission of MRSA to other individuals, particularly in healthcare environments. Furthermore, colonized individuals are at a higher risk of developing subsequent invasive infections if the bacteria enter the bloodstream or deep tissues through surgical incisions, intravenous lines, or skin trauma. This code is critical for infection control surveillance, prompting the implementation of contact precautions and potential decolonization protocols (such as mupirocin nasal ointment or chlorhexidine washes) to mitigate the spread of multi-drug resistant organisms. It is also used in preoperative assessments to guide prophylactic antibiotic selection, as standard cephalosporins are ineffective against MRSA.
Distinguish between carrier status and active infection for accurate coding.
Example: Patient is an asymptomatic carrier of MRSA identified via pre-operative nasal swab screening. There are no clinical signs of active skin or soft tissue infection, and systemic inflammatory markers are within normal limits. This carrier status is noted for infection control precautions during the upcoming total knee arthroplasty. Billing Focus: Explicitly stating 'asymptomatic' and 'carrier status' avoids incorrect coding for an active infection. Risk Adjustment: Carrier status itself does not typically map to an HCC but distinguishes the encounter from high-risk active infections like MRSA sepsis (A41.02) which carries significant risk weight.
Billing Focus: Documentation must specify the absence of active infection symptoms to support Z22.322 rather than B95.62.
Document the specific site of colonization to support medical necessity for decolonization protocols.
Example: Surveillance cultures of the bilateral nares and axilla are positive for Methicillin resistant Staphylococcus aureus. Patient is currently colonized. Plan: Initiate decolonization with mupirocin 2 percent ointment to nares twice daily and chlorhexidine gluconate 4 percent body washes for 5 days. Billing Focus: Identification of the specific anatomical site (nares/axilla) justifies the use of topical agents and related CPT codes for laboratory testing. Risk Adjustment: Accurately reflects the complexity of managing a patient with chronic colonization in multiple sites who may be at higher risk for future post-surgical complications.
Billing Focus: Site specificity supports the necessity of localized treatments like mupirocin nasal ointment.
Clearly link carrier status to the encounter rationale, such as pre-operative screening or admission surveillance.
Example: Encounter for pre-admission screening prior to scheduled elective spinal fusion. Patient found to be a carrier of MRSA (Z22.322). No active drainage or cellulitis noted at this time. Billing Focus: Documentation of the 'encounter for screening' (Z11.52) should be sequenced first if the carrier status was not previously known, but Z22.322 is used to describe the findings. Risk Adjustment: Provides context for the increased intensity of service required for isolation and sterilization during the hospital stay.
Billing Focus: Linking carrier status to screening codes like Z11.52 helps clarify the purpose of the laboratory charges.
Update documentation when carrier status transitions to a personal history status.
Example: Patient has a personal history of MRSA colonization; however, the most recent surveillance swabs from 48 hours ago were negative at all sites following a full decolonization cycle. Currently, the patient is not a carrier. Billing Focus: Transition from Z22.322 (Carrier) to Z86.14 (Personal history of MRSA infection) once the carrier state is resolved. Risk Adjustment: History codes represent a different risk profile than active colonization and may impact future screening requirements.
Billing Focus: Prevents over-billing for carrier status when the condition is resolved or 'history of' only.
Note the presence of co-morbidities that increase the risk of carrier-to-infection transition.
Example: Patient is an MRSA carrier (Z22.322) with comorbid Type 2 Diabetes Mellitus with chronic foot ulcer and Stage 3 Chronic Kidney Disease. Due to increased risk of secondary MRSA infection of the existing ulcer, strict contact precautions and daily skin assessments are initiated. Billing Focus: Documenting the comorbidities (E11.621, N18.31) alongside the carrier status supports the complexity of the medical decision making. Risk Adjustment: Captures the high severity of illness (SOI) and risk of mortality (ROM) when a carrier state exists in an immunocompromised or diabetic patient.
Billing Focus: Documenting comorbidities supports higher level E/M codes such as 99214 due to increased risk of complications.
This is the primary laboratory test used to identify the carrier state defined by Z22.322.
Used when screening via culture rather than rapid molecular methods.
Appropriate for a brief follow-up to inform a patient of a positive screening result where no complex treatment is needed.
Used when the physician must discuss decolonization protocols and provide education on infection control to a carrier.
Applicable if the patient has significant comorbidities (e.g., CKD, Diabetes) that complicate the management of the carrier state.
Used for a new patient evaluation where the only concern is an incidental finding of MRSA carrier status.
Standard new patient referral for management of a carrier state found during pre-op screening.
Used by hospital-based clinics for the facility component of an MRSA screening or follow-up visit.
Could be used for counseling a patient on household transmission risks associated with being an MRSA carrier.
Used if a swab from a non-respiratory site (e.g., skin fold) is being used to screen for MRSA carrier status.